Antileukemic activity and mechanism of action of the novel PI3K and histone deacetylase dual inhibitor CUDC-907 in acute myeloid leukemia

Induction therapy for patients with acute myeloid leukemia (AML) has remained largely unchanged for over 40 years, while overall survival rates remain unacceptably low, highlighting the need for new therapies. The PI3K/Akt pathway is constitutively active in the majority of patients with AML. Given...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Haematologica
Egile Nagusiak: Li, Xinyu, Su, Yongwei, Madlambayan, Gerard, Edwards, Holly, Polin, Lisa, Kushner, Juiwanna, Dzinic, Sijana H., White, Kathryn, Ma, Jun, Knight, Tristan, Wang, Guan, Wang, Yue, Yang, Jay, Taub, Jeffrey W., Lin, Hai, Ge, Yubin
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: Ferrata Storti Foundation 2019
Gaiak:
Article
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC6821619/
https://ncbi.nlm.nih.gov/pubmed/30819918
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3324/haematol.2018.201343
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak